Biogen Inc.
Location
Massachusetts
Founded
1978-02-28
Website
Risk Signals
2647 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Pharmaceutical Preparations, Biological Products, Except Diagnostic Substances, Commercial Physical and Biological Research), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about Biogen Inc.
Live alerts from global media, monitored by Business Radar
2025-04-14 (marketbeat.com)
Causeway Capital Management LLC Purchases New Shares in Biogen Inc. (NASDAQ:BIIB)
Causeway Capital Management LLC acquired a new position in shares of Biogen Inc. (NASDAQ:BIIB - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 281,702 shares of the biotechnology company's st
Read more
2025-04-11 (investing.com)
UBS cuts the price target of the Biogen shares to € 134 from € 157 from Investing.com
UBS cuts the price target of the Biogen shares to € 134 from € 157
Read more
2025-04-08 (moomoo.com)
Piper Sandler Maintains Biogen(BIIB.US) With Hold Rating, Cuts Target Price to $135
PiperSandler analyst David Amsellem maintains $Biogen(BIIB.US)$ with a hold rating, and adjusts the target price from $138 to $135.According to TipRanks data, the analyst has a success rate of 42.1%
Read more
2025-04-03 (investing.com)
RBC Capital cuts Biogen stock price target to $221 By
On Thursday, RBC Capital Markets adjusted its financial outlook on Biogen shares, reducing the price target to $221 from $225 while maintaining an Outperform rating. According to InvestingPro data, the stock is currently trading near its 52-week low of $128.51, with analyst targets ranging from $135 to $342, suggesting significant potential upside. The company maintains a healthy financial profile with an InvestingPro Financial Health score of "GOOD." Brian Abrahams of RBC Capital Markets shared insights on Biogen's quarterly performance, noting an expectation for revenues to align closely with consensus estimates at $2.25 billion versus the $2.24 billion forecast. This comes as the company's trailing twelve-month revenue stands at $9.68 billion, with a robust gross profit margin of 76%.
Read more
2025-03-20 (marketbeat.com)
Harvest Fund Management Co. Ltd Grows Stock Holdings in Biogen Inc. (NASDAQ:BIIB)
Harvest Fund Management Co. Ltd grew its stake in Biogen Inc. (NASDAQ:BIIB - Free Report) by 27.8% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 8,576 shares of the biotechnology company's stock after purc
Read more
2025-02-13 (asianetnews.com)
Biogen Stock Slides To Fresh 12-Year Lows As Profit Outlook Misses, But Retail Snaps Up The Dip-
The company's breakthrough Alzheimer's drug, Leqembi, generated $87 million in Q4 sales, well ahead of the $67 million analysts expected.
Read more
2025-02-12 (schaeffersresearch.com)
Hot Inflation Data Pressures Stock Futures Lower - Schaeffer's Investment Research
Stock futures are sharply lower this morning, as investors unpack hotter-than-expected inflation data for January
Read more
2025-01-16 (marketbeat.com)
Czech National Bank Acquires 1,923 Shares of Biogen Inc. (NASDAQ:BIIB)
Czech National Bank boosted its position in shares of Biogen Inc. (NASDAQ:BIIB - Free Report) by 6.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 31,595 shares of the biotechnology company's stock after acquiring
Read more
2025-01-16 (investing.com)
Biogen stock touches 52-week low at $144.96 amid challenges By
Biogen stock touches 52-week low at $144.96 amid challenges
Read more